IVIG To SCIG Transition denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies the IVIG-to-SCIG Transition as Non-Formulary

Blue Cross Blue Shield formularies can vary significantly by plan year and benefit design. A specific SCIG product may sit on a non-preferred tier, require a formulary exception, or simply not appear on the plan's drug list even though IVIG products do — creating a non-formulary denial when the prescriber orders a particular SCIG brand. This type of denial is procedurally straightforward to challenge because formulary exception and medical-necessity pathways exist precisely for situations where the formulary drug is clinically inappropriate or unavailable.

## Why This Denial Is Appealable

Federal law requires plans to have a formulary exception process. Under ACA §2719, you may appeal a non-formulary denial through internal appeal and then independent external review. Under ERISA §503, employer-plan members have full-and-fair review rights. Check your EOB for internal appeal deadlines (often 180 days) and note that external review requests generally must be filed within 4 months of exhausting internal options. If the absence of coverage poses an urgent clinical risk, request an expedited appeal.

## The Concrete Appeal Process

1. Confirm which, if any, SCIG product does appear on your plan's current formulary. 2. If a formulary alternative exists but is clinically inappropriate for this patient (different route frequency, known tolerability issue, device incompatibility), document why the prescribed product is necessary. 3. File a formulary exception request alongside or as part of the internal appeal, supported by a prescriber letter. 4. If the exception is denied, escalate to external review.

## Documentation to Gather

• Formulary comparison: A copy of the current BCBS formulary showing which immunoglobulin products are covered, used to argue that no formulary-covered SCIG alternative is clinically equivalent for this patient.
• Prescriber letter: Explains why the specific ordered SCIG product is medically necessary and, if a formulary alternative exists, why it is clinically inappropriate or contraindicated for this patient's circumstances.
• Diagnosis and treatment history: Chart notes confirming the established need for immunoglobulin replacement therapy.
• FDA prescribing label: For the ordered product, confirming it is FDA-approved for the patient's diagnosis.
• Clinical rationale for SCIG over IVIG: Documents the transition is not merely preferential but clinically driven.

## Criteria-Mapping Structure

Obtain both the BCBS formulary exception policy and the coverage policy for immunoglobulin therapy. Map every exception criterion to chart evidence:

| Formulary Exception Criterion | Your Supporting Evidence | |---|---| | [Copy exact criterion — e.g., "formulary alternative is contraindicated"] | [Prescriber letter section, chart note] | | [Copy exact criterion — e.g., "formulary alternative was tried and failed"] | [Dates, outcomes documented in chart] |

A precise, criterion-anchored exception request submitted with the prescriber letter and FDA label is the fastest path to approval.